Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements

PR Newswire October 6, 2021

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

PR Newswire October 4, 2021

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo

PR Newswire September 23, 2021

RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients

PR Newswire September 14, 2021

RHB-107 P2/3 COVID-19 Study South Africa Approval

Accesswire September 13, 2021

RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval

PR Newswire September 13, 2021

RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis

PR Newswire September 7, 2021

RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek

Accesswire September 7, 2021

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

PR Newswire September 7, 2021

RedHill to Present at HCW & Cantor Conferences

Accesswire September 2, 2021

RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences

PR Newswire September 2, 2021

RedHill Reports Second Quarter 2021 Results

Accesswire August 26, 2021

RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights

PR Newswire August 26, 2021

RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition

Accesswire August 26, 2021

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant

PR Newswire August 26, 2021

RedHill Announces Two New U.S. Patents

Accesswire August 23, 2021

RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's

PR Newswire August 23, 2021

RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021

PR Newswire August 19, 2021

RedHill Settles Movantik(R) Apotex Patent Litigation

Accesswire July 22, 2021

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex

PR Newswire July 22, 2021